Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring stage II colon cancer, stage III colon cancer, stage IV colon cancer, stage II gastric cancer, stage III gastric cancer, stage IV gastric cancer, recurrent gastric cancer, stage II pancreatic cancer, stage III pancreatic cancer, recurrent pancreatic cancer, stage II rectal cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, stage II esophageal cancer, stage III esophageal cancer, stage IV esophageal cancer, recurrent esophageal cancer, adenocarcinoma of the stomach, small intestine adenocarcinoma, localized gallbladder cancer, unresectable gallbladder cancer, recurrent gallbladder cancer, localized extrahepatic bile duct cancer, unresectable extrahepatic bile duct cancer, recurrent extrahepatic bile duct cancer, recurrent small intestine cancer, adenocarcinoma of the esophagus, adenocarcinoma of the colon, adenocarcinoma of the rectum, adenocarcinoma of the gallbladder, adenocarcinoma of the extrahepatic bile duct, adenocarcinoma of the pancreas, stage IV pancreatic cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed stage II, III, or IV adenocarcinoma of the gastrointestinal tract originating in 1 of the following: Esophagus Stomach Pancreas Small intestine Colon or rectum Gall bladder Extrahepatic bile ducts Ampulla of Vater Completed standard therapy and at risk of recurrent disease OR has relatively stable metastatic disease and a life expectancy of at least 6 months Carcinoembryonic antigen (CEA)-producing tumor as evidenced by detectable blood levels of CEA or positive for CEA on immunohistochemical staining Human Leukocyte Antigen (HLA)-A2+ PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Southwest Oncology Group (SWOG) 0-1 Life expectancy: See Disease Characteristics Hematopoietic: White Blood Count (WBC) at least 4,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 8 g/dL Hepatic: Serum Glutamic Oxalacetic Transaminase (SGOT) or Serum Glutamic Pyruvic Transaminase (SGPT) no greater than 3 times upper limit of normal Hepatitis B and C negative Renal: Creatinine no greater than 2.0 mg/dL Other: No other prior malignancy unless currently disease free and off all therapy for that malignancy Early skin cancer allowed No AIDS HIV negative Not pregnant or nursing Fertile patients must use effective contraception during and for 30 days after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 4 weeks since prior surgery Other: No other concurrent therapy for malignancy
Sites / Locations
- University of Texas Medical Branch